Tenderwize
Wróć do wyszukiwania

Non-exclusive rebate agreement for Golimumab

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 126 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Golimumab (ATC-Code nach WHO: L04AB06)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice refers to key documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') but...

The notice states that participation documents must be submitted via the DTVP communication function and not via the bi...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Golimumab (ATC L04AB06).
  • Open-House participation model: all interested pharmaceutical companies may join if they meet and accept the participation conditions.
Pokaż pełne podsumowanie

This is an Open-House framework-style supply arrangement for non-exclusive pharmaceutical rebate agreements for Golimumab (ATC L04AB06) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the stated conditions may join during the participation period, with no individual negotiations and no exclusivity. The contract period runs until 31.12.2026 at the latest. Submission is electronic via DTVP communication, but not via the bidder tool; the first participation deadline was updated to 03.12.2025. Procurement documents are referenced but their extracted text is not provided, so key document-based details remain unverified.

Ryzyka

The notice refers to key documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') but...

The notice states that participation documents must be submitted via the DTVP communication function and not via the bi...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicines.

Eligibility

  • The bidder must submit the completed 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' to evidence absence of mandatory/optional exclusion grounds under §§ 123, 124 GWB.

Administrative

  • The bidder must submit the 'Eigenerklärung Russlandsanktionen' confirming no Russia-related link within the meaning of Article 5k of Regulation (EU) 833/2014 as amended.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive rebate agreement for Golimumab

Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for medicines containing the active substance Golimumab. The arrangement is described as an Open-House model, with no exclusivity and no individual negotiations. Performance/place of performance is stated as Dresden, Germany, but this is the notice geography and not necessarily the delivery model details.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Dec 2025 - Dec 2026

Kategoria

Pharmaceutical products

Termin

Deadline Dec 31, 2026

Szczegóły zamówienia

Data publikacji
20 Oct 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
692978-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3